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Abstract Australia is currently well placed to contribute
to the global growth of human stem cell research. However, as
the science has progressed, authorities have had to deal with
the ongoing challenges of regulating such a fast moving field
of scientific endeavour. Australia’s past and current approach
to regulating the use of embryos in human embryonic stem
cell research provides an insight into how Australia may
continue to adapt to future regulatory challenges presented by
human stem cell research. In the broader context, a number
of issues have been identified that may impact upon the
success of future human stem cell research in Australia.
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Introduction
Scientific research in Australia continues to rapidly prog-
ress and, as in many other countries, the legal and
regulatory structures in place have tended to struggle to
keep up. In relation to human stem cell research, the past
decade has witnessed not only extraordinary scientific
developments, but also a process of consultative and
deliberate regulatory reform in Australia, specifically in
relation to aspects of the use of human embryos for the
purposes of human embryonic stem cell research.
In 2001, the House of Representatives Standing Commit-
tee on Legal and Constitutional Affairs produced a report on
human cloning and stem cell research [1] that culminated in
the enactment of the Research Involving Human Embryos
Act 2002 (Cth) and the Prohibition of Human Cloning Act
2002 (Cth). Both these Acts have been recently amended as
result of a further inquiry in late 2005. Despite this
reasonably timely and continuing process of regulatory
reform in relation to the use of embryos in human embryonic
stem cell research, there are still issues in Australia that
remain unaddressed.
This commentary briefly canvasses the background to the
current regulation of human stem cell research. It focuses
primarily on the example of the changing regulatory regime
for use of embryos in human embryonic stem cell research and
briefly discusses issues relevant to adult stem cell research. It
concludes by considering a range of issues that may influence
the future of human stem cell research in Australia.
Human Embryonic Stem Cell Research
Background to the Current Position
To gain an insight into the process of regulatory reform that
Australia has adopted, it is useful to consider the position in
Australia in relation to use of human embryonic stem cells.
This may provide an indication of how reform in this area
will be approached in the future.
Like many other countries, the regulation of human
embryonic stem cell research is treated differently—
ethically and legally—from research on human adult stem
cells [1]. Consequently, although Australia is working
towards a unified national approach to the use of embryos
in human embryonic stem cell research, the same cannot be
said of the use of adult stem cells.
Australia’s federal structure means that, in the absence of
an agreement to undertake a coordinated approach, each
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State and Territory Government has jurisdiction to legislate
on the regulation of scientific research. The (almost)
uniform regulation of human embryonic stem cell research
in Australia has only been made possible due to the States
and Territories agreeing to implement uniform legislation in
this area to mirror the Federal legislation [2].
In 2002 the Federal Government enacted the Prohibi-
tion of Cloning Act 2002 (Cth) and the Research Involving
Human Embryos Act 2002 (Cth) and State and Territory
legislation was subsequently enacted to mirror those acts.
These initial steps at regulating research involving human
embryos were relatively conservative. The key features of
the legislation setting up the regime were:
➢ Absolutely prohibiting the practice of reproductive and
therapeutic cloning, the creation of chimera embryos
and commercial trading in gametes or embryos, by
making those practices criminal [3];
➢ Prohibiting the use of excess Assisted Reproductive
Technology (ART) embryos [4] for the purpose of
research unless authorised by a licence from the
Embryo Research Licensing Committee of the National
Health and Medical Research Council (NHMRC). This
meant research proposals involving use of embryos
required institutional human research ethics committee
approval and a licence from the NHMRC. In addition,
where research resulted in the destruction of an embryo,
then the legislation specified that the embryo must have
been created prior to 5 April 2002 [5].
➢ A requirement for review of the regime by 19 December
2005 [6].
Although not everyone agreed with the restrictions
imposed by the legislation, most agreed that introducing
some regulatory regime to govern this area was desirable
[1].
Therefore, from the outset a cautious approach was
taken, but also one conscious of the rapid developments in
science and shifts in public opinion over relatively short
periods of time. Sensibly, a requirement for future review
was built into the legislation.
Review and Reform
The review mandated by the 2002 legislation was under-
taken by the Government appointed Legislation Review
Committee that became known as the ‘Lockhart Review’
(after the late Hon John Lockhart who chaired the
Committee). The Lockhart Review made 54 recommenda-
tions in December 2005. Its process of review became well
known for its widely inclusive consultation and an
approach which attempted to find common ground in an
area which, it was recognised, there existed a divergence of
views [7]. Part of its rationale stemmed from the reasoning
that [8]:
the higher the potential benefits of an activity, the
greater the need for ethical objections to be of a high
level and widely accepted in order to prevent that
activity. Conversely, where benefits are not yet
established, or where there is widespread and deeply
held community objection, then total prohibition
through the legal system may be justified. In addition,
even though some people think that an activity is
unethical, it does not necessarily follow that the
activity should be made illegal. Furthermore, the wider
the range of ethical views on a particular activity, the
weaker becomes the case for declaring that activity to
be illegal, with all the attendant consequences of
criminal conduct.
The Lockhart Review recognised that embryonic stem cell
research findings have not yet translated into clinical trials or
treatment but that, to date, the use of excess ART embryos to
derive embryonic stem cell lines had contributed to progress
in the derivation and culture of cells and methodology for
promoting growth of different types of cells [8].
Perhaps the most significant decision made by the
Lockhart Review was recommending the ban on the creation
of embryos (via means other than by fertilisation of a human
egg by a human sperm) for the purposes of research be
removed and should be able to be authorised by licence. The
Committee made a distinction between embryos created by
the normal process of fertilisation and those created by
somatic cell nuclear transfer or other activation methods after
concluding that, ‘there was an overall acceptance that human
embryos created by the fertilisation of a human egg by a
human sperm are entities of some social and ethical
significance because of their association with the start of
human life’ [8]. A number of other recommendations were
made that aimed to clarify or strengthen the system of
regulation at that time.
Some recommendations made by the Committee were
considered particularly controversial. It recommended that,
in order to reduce the need for human eggs, transfer of
human somatic cell nuclei into animal eggs should be
allowed, under licence, for the creation and use of human
embryos for research, including the production of human
embryonic stem cells. This recommendation was one of the
few that was not taken up in the subsequent amending
legislation of 2006. The situation in this regard can be
contrasted with more liberal jurisdictions, such as the UK.
Current Regulatory Position
Following the release of the Lockhart Review’s Report it
initially seemed that the recommendations were to be
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ignored by the Federal Government. However, following the
initiation of a private members bill by Senator Patterson, and
the Prime Minister (at that time) allowing a conscience vote
on the bill, the majority of recommendations—including
allowing the creation of embryos (other than by fertilisation
of a human egg by human sperm) for the purposes of
research to be licensed—have passed into law.
Since the Prohibition of Human Cloning for Reproduction
and the Regulation of Human Embryo Research Amendment
Act 2006 (Cth) was passed, a number of States and
Territories (but not all) have passed, or are in the process
of passing, equivalent legislation to give effect to the
amending Federal legislation [9]. Until corresponding
legislation is passed in all Australian jurisdictions the
regulatory regime cannot truly be considered a uniform
national regime.
The regulatory position today in relation to human
embryonic stem cell research (in those jurisdictions that
have passed equivalent legislation) can therefore be
characterised by the following major features:
➢ Absolutely prohibiting the practice of reproductive
cloning, creation of chimera embryos and commercial
trading in gametes or embryos, by making those
practices criminal;
➢ Prohibition of the following practices unless authorised
by licence from the NHMRC [10, 11]:
◦ The use of excess ART embryos for the purpose of
research;
◦ The creation or development of embryos (including
where the embryo contains genetic material of more
than two persons) created other than by a process of
fertilisation of a human egg by a human sperm;
◦ The use of precursor cells taken from a human
embryo or fetus to create a human embryo;
◦ The creation or development of a hybrid embryo for
the purposes of testing sperm quality.
The legislation specifies that authority cannot be given for
any embryo to develop for a period of more than 14 days.
➢ For a licence to be obtained, the NHMRC licensing
committee must consider that the relevant NHMRC
guidelines (e.g. the National Statement on Ethical
Conduct in Human Research, 2007 and the Ethical
Guidelines on the Use of Assisted Reproductive Technol-
ogy in Clinical Practice and Research, 2007) have been
complied with [10, 12].
➢ Similar to the original 2002 legislation, built into the
new amendments is the requirement for future legisla-
tive review following the third anniversary of the
amending legislation in late 2009.
The most recent report to Parliament issued by the
NHMRC Embryo Research Licensing Committee indicates
that a total of thirteen licences have been issued under the
legislation, eleven of which were current as at 30 September
2008 [13]. Only three of these licences have been granted for
the creation of embryos other than by a process of
fertilisation of a human egg by a human sperm, i.e. via
somatic cell nuclear transfer.
Adult Stem Cells
Unlike the approach taken to regulating the use of embryos
for human embryonic stem cell research discussed above,
those researching adult stem cells are subject to varying
regulatory requirements.
For research involving adult stem cells, the NHMRC
National Statement on Ethical Conduct in Human Research
is still applicable and required to be complied with by those
funded under the NHMRC, the Australian Research
Council and the Australian Vice-Chancellor’s Committee.
However, in the absence of legislation requiring compli-
ance, there would appear to be no legal compulsion for
researchers receiving funding from other sources to comply
with the National Statement [14]. In all likelihood compli-
ance with institutional human research ethics committee
approval will still be required.
Researchers should, however, be aware of jurisdiction
specific legislation that may impact on their research of
adult stem cells. For example, legislation dealing with the
use of human tissue and transplantation [15], which may be
relevant to some research, varies between different Austra-
lian jurisdictions.
Adult Stem Cells—Clinical Trials
Researchers may also need to consider the regulatory
framework of the Therapeutic Goods Administration if
their research on adult stem cells progresses to the point of
developing a potential therapeutic product. (Obviously,
when research on human embryonic stem cells reaches this
point, this will also become a relevant consideration for
those working in that area.)
Rapid progress made in this area means that the
development of potential therapeutic products from adult
stem cells, requiring clinical trials and regulatory approval,
is fast becoming a reality [16, 17]. However, given
Australia’s history of cautious regulatory reform in the area
of human embryonic research, it is perhaps not surprising to
find that Australian regulators are struggling to keep up
with these steps forward.
Currently, the Therapeutic Goods Administration—the
national body charged with ensuring therapeutic goods
available in Australia are of an acceptable standard under
the Therapeutic Goods Act 1989 (Cth)—admits that the
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existing therapeutic goods regulatory framework is current-
ly not well adapted for human cell and tissue therapies.
The timeliness of the recently released International
Society for Stem Cell Research (ISSCR) Guidelines for the
Clinical Translation of Stem Cells [18], which addresses
cell processing and manufacture, preclinical studies and
clinical research, has highlighted the current failure of the
Australian regulators to stay abreast of these developments.
Although work is currently underway to develop a new
human cellular and tissue therapies regulatory framework
(said to be largely consistent with the ISSCR guidelines
[17]) this is not expected to be implemented until 2010,
with a transition period for products to move into the new
scheme.
Other Issues Affecting Research in Australia
An Australian Stem Cell Bank
The Lockhart Review identified that there was ‘overall
strong support for an Australian stem cell bank in order to
improve access to stem cell lines for research and to
provide a quality control mechanism for stem cell
research’[8]. It recommended that the feasibility of estab-
lishing a national stem cell bank at the Australian Stem Cell
Centre be considered. Despite this specific recommenda-
tion, the latest amendments to the legislation have failed to
establish a national stem cell bank. However, any future
development to implement an Australian stem cell bank
should not be ruled out as the current legislation requires
specific reconsideration of a national stem cell bank in
subsequent reviews.
Funding and Collaboration
The advancement of human stem cell research in
Australia will obviously be helped or hindered by the
availability of funding for research. However, future
advancement is likely to be supported by the growing
number of formal, and informal, collegiate networks of
scientists with expertise.
Researchers of adult stem cells received a boost with the
recent establishment of the multi-million dollar National
Centre for Adult Stem Cell Research at Griffith University
in Queensland. In addition, the newly inaugurated Austral-
asian Society for Stem Cell Research (ASSCR) was
launched in November 2008 as a group that intends to
‘fly the flag’ for stem cell research in Australia [17].
ASSCR aims to promote scientific interests and facilitate
networking amongst the stem cell research community in
Australasia. It aims to foster and enhance links between
researchers and clinicians to allow translation of research
and also to foster links with other disciplines including
bioethics, law and sociology and provide information to the
public [19].
On the other hand, last year, reports that the Australian
Stem Cell Centre suffered from managerial problems and
internal disputes culminated in the departure of its CEO in
July, the resignation of its Independent Board in September
and an organisational restructure announced in October.
Fears as to the continued funding of the Australian Stem
Cell Centre by the Victorian Government after 2011
surfaced in the media late in 2008.
Encouragingly, Australia was the fifth ranked ‘over-
performing’ country in research related to human embry-
onic stem cells (based on publication output) in 2008 [20].
In addition Australian scientists have been recognised for
the increasing numbers of successful international collabo-
rations; a trend which appears to be increasing [17]. The
international exchange of stem cells has also been helped
by the removal of a previous restriction on import and
export of these materials [21].
Conclusion
In Australia, the regulation of human stem cell research
and, particularly, the regulation of human embryonic stem
cell research, has been characterised by progressive review
and public consultation. This process has created much
debate and has resulted in Australia cautiously and
incrementally moving towards a more permissive regulato-
ry regime. However, the current regime does not attempt to
match the more permissive schemes of countries abroad
and the swift advances in stem cell science have not been
matched by local regulators. Nonetheless, recent history
demonstrates that Australia is not averse to changing its
regulatory position in the rapidly moving field of human
stem cell research. The 2009 legislative review may see it
continue to move to allow further types of research within
its regulatory regime.
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